249 related articles for article (PubMed ID: 30500954)
61. Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.
Gu X; Hu Z; Ebrahem Q; Crabb JS; Mahfouz RZ; Radivoyevitch T; Crabb JW; Saunthararajah Y
J Biol Chem; 2014 May; 289(21):14881-95. PubMed ID: 24695740
[TBL] [Abstract][Full Text] [Related]
62. The master regulator FUBP1: its emerging role in normal cell function and malignant development.
Debaize L; Troadec MB
Cell Mol Life Sci; 2019 Jan; 76(2):259-281. PubMed ID: 30343319
[TBL] [Abstract][Full Text] [Related]
63. The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer.
Wang E; Kawaoka S; Roe JS; Shi J; Hohmann AF; Xu Y; Bhagwat AS; Suzuki Y; Kinney JB; Vakoc CR
Elife; 2015 Apr; 4():e06377. PubMed ID: 25919951
[TBL] [Abstract][Full Text] [Related]
64. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.
Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194
[TBL] [Abstract][Full Text] [Related]
65. Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression.
Yang L; Zhu JY; Zhang JG; Bao BJ; Guan CQ; Yang XJ; Liu YH; Huang YJ; Ni RZ; Ji LL
Tumour Biol; 2016 Mar; 37(3):4115-26. PubMed ID: 26490982
[TBL] [Abstract][Full Text] [Related]
66. Clonal origins of ETV6-RUNX1⁺ acute lymphoblastic leukemia: studies in monozygotic twins.
Alpar D; Wren D; Ermini L; Mansur MB; van Delft FW; Bateman CM; Titley I; Kearney L; Szczepanski T; Gonzalez D; Ford AM; Potter NE; Greaves M
Leukemia; 2015 Apr; 29(4):839-46. PubMed ID: 25388957
[TBL] [Abstract][Full Text] [Related]
67. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
68. The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter.
Chen G; Liu A; Xu Y; Gao L; Jiang M; Li Y; Lv N; Zhou L; Wang L; Yu L; Li Y
FEBS J; 2019 Mar; 286(5):901-912. PubMed ID: 30637949
[TBL] [Abstract][Full Text] [Related]
69. Runx1 and RORγt Cooperate to Upregulate IL-22 Expression in Th Cells through Its Distal Enhancer.
Sekimata M; Yoshida D; Araki A; Asao H; Iseki K; Murakami-Sekimata A
J Immunol; 2019 Jun; 202(11):3198-3210. PubMed ID: 31028121
[TBL] [Abstract][Full Text] [Related]
70. Predicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemia.
Hajingabo LJ; Daakour S; Martin M; Grausenburger R; Panzer-Grümayer R; Dequiedt F; Simonis N; Twizere JC
Mol Biol Cell; 2014 Dec; 25(24):3973-85. PubMed ID: 25273558
[TBL] [Abstract][Full Text] [Related]
71. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
72. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
[TBL] [Abstract][Full Text] [Related]
73. A DNA Contact Map for the Mouse Runx1 Gene Identifies Novel Haematopoietic Enhancers.
Marsman J; Thomas A; Osato M; O'Sullivan JM; Horsfield JA
Sci Rep; 2017 Oct; 7(1):13347. PubMed ID: 29042628
[TBL] [Abstract][Full Text] [Related]
74. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer.
Tian Y; Wang G; Hu Q; Xiao X; Chen S
J Cell Biochem; 2018 Apr; 119(4):3706-3715. PubMed ID: 29236325
[TBL] [Abstract][Full Text] [Related]
75. The enhancer RNA
Tan SH; Leong WZ; Ngoc PCT; Tan TK; Bertulfo FC; Lim MC; An O; Li Z; Yeoh AEJ; Fullwood MJ; Tenen DG; Sanda T
Blood; 2019 Jul; 134(3):239-251. PubMed ID: 31076442
[TBL] [Abstract][Full Text] [Related]
76. KIT
Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
[TBL] [Abstract][Full Text] [Related]
77. Histone Chaperone HIRA in Regulation of Transcription Factor RUNX1.
Majumder A; Syed KM; Joseph S; Scambler PJ; Dutta D
J Biol Chem; 2015 May; 290(21):13053-63. PubMed ID: 25847244
[TBL] [Abstract][Full Text] [Related]
78. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
[TBL] [Abstract][Full Text] [Related]
79. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
[TBL] [Abstract][Full Text] [Related]
80. The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1.
Lécuyer E; Herblot S; Saint-Denis M; Martin R; Begley CG; Porcher C; Orkin SH; Hoang T
Blood; 2002 Oct; 100(7):2430-40. PubMed ID: 12239153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
